Actinium Pharmaceuticals Inc (ATNM): EDISON EQUITY RESEARCH

Reply Private New

Next 10 Prev Next

Send PM Follow Ignore

Followers	21
Posts	949
Boards Moderated	0
Alias Born	08/15/2012

MrMr1

Re: oxnous post# 41

Monday, 02/09/2015 3:10:12 PM

Monday, February 09, 2015 3:10:12 PM

EDISON EQUITY RESEARCH - ACTINIUM PHARMACEUTICALS

Source: InvestorsHub NewsWire
EDISON EQUITY RESEARCH: ACTINIUM PHARMACEUTICALS - PUBLIC OFFERING TO FUND LATE-STAGE DEVELOPMENT

Actinium Pharmaceuticals is developing targeted radiation therapies (both a- and ß-particle based) that offer the prospect of highly selective tumour cell killing with limited side effects compared to existing therapies. The underwritten public offering consists of 4.44m shares and 3.33m warrants (exercisable over four years) at a combined price of $4.50. The $20m (gross) raised will be used to progress the late-stage clinical programmes to key value inflection points, notably Iomab-B in a pivotal Phase III trial.

Actinium Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops drugs for the treatment of various cancers. Actimab-A is in Phase I/II clinical trials for acute myeloid leukaemia. Iomab-B is entering Phase II/III trials for myeloconditioning for hematopoietic stem cell transplantation.

To view our full report, please click here

Click here to view all of Edison Investment Research’s published reports